Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This Phase I study will evaluate the safety, tolerability and pharmacokinetic properties of
escalating single doses of reformulated MMV390048 when administered to healthy men and women
of non-childbearing potential (WNCBP) under fasted conditions (Part A).
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborators:
Clinical Network Services (CNS) Pty Ltd Q-Pharm Pty Limited QIMR Berghofer Medical Research Institute